University of North Carolina, Chapel Hill

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of North Carolina, Chapel Hill sits in the top decile of US sponsors by registered trial count (#28 of 15,742 sponsors by registered trial count).

1,109 total trials 108 currently recruiting 881 completed early-phase tilt top decile by trial count

University of North Carolina, Chapel Hill: 1,109 sponsored US clinical trials, 108 recruiting.

University of North Carolina, Chapel Hill sponsors 1,109 registered US clinical trials on ClinicalTrials.gov, 108 of them currently recruiting, and 881 completed. 69 of these trials are in Phase 3-4 (later-stage) and 203 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 17 trials.

Top-decile sponsor footprint

University of North Carolina, Chapel Hill ranks in the top decile of sponsors by registered trial count (#28 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 69/100

881 of 962 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,109 total, page 13 of 23

COMPLETED NA

Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection

NCT02384395

COMPLETED NA

Patient Education to Improve Pain Management in Older Adults With Acute Musculoskeletal Pain: A Pilot Randomized Trial

NCT02438384

COMPLETED NA

Chronic Lumbosacral Radiculopathy: Impact of an Analgesic Dietary Intervention on Pain & Function

NCT02531711

TERMINATED Early Phase 1

19F MRI of Ventilation in Subjects With Cystic Fibrosis Undergoing Treatment for Pulmonary Exacerbation

NCT03497117

COMPLETED Phase 2

Study of Orofacial Pain and PropRANOlol

NCT02437383

COMPLETED

Optimizing Drug Doses in Critically Ill

NCT02437838

COMPLETED

Transitioning HIV+ Adolescents to Adult Care: Exploring Adolescent and Adult Medicine Clinics Role in the Process

NCT02785302

COMPLETED NA

Health Experiences & Early Life Disadvantages

NCT02400593

COMPLETED Phase 4

Intravenous Exenatide in Patients With Acute Brain Injury

NCT02058940

COMPLETED

Autoimmune Paradoxical Reactions in IBD Longitudinal Cohort

NCT02503514

COMPLETED NA

Normalizing HPV Vaccination in Preteens With a Serious Video Game

NCT04627298

COMPLETED Early Phase 1

19F MRI to Evaluate Regional Ventilation in Healthy Subjects and Subjects With Cystic Fibrosis

NCT03489590

COMPLETED Phase 2

Oxytocin Treatment of Alcohol Dependence

NCT02251912

COMPLETED Phase 2

Emotional Processing and Oxytocin Mechanisms in Premenstrual Dysphoric Disorder: A Pilot Study

NCT02508103

COMPLETED

Initial and Chronic Methicillin Resistant Staphylococcus Aureus (MRSA) Infection in Cystic Fibrosis (CF)

NCT02684422

COMPLETED Phase 4

Tolvaptan For Worsening Outpatient Heart Failure: Role of Copeptin In Identifying Responders

NCT02476409

COMPLETED

Adolescent Vaccination in Pharmacies

NCT01960088

COMPLETED NA

Using Question Prompt Lists During Pediatric Asthma Visits to Increase Adolescent Involvement

NCT02498834

TERMINATED NA

Diagnosis and Monitoring of Eosinophilic Esophagitis Using the Cytosponge

NCT02114606

COMPLETED NA

Testing the Effects of the CDSMP Among Lower-to-Middle Wage Workers

NCT04116463

COMPLETED NA

Acute Partner and Social Contact Referral: iKnow

NCT02467439

COMPLETED NA

Breakfast Meal Replacement

NCT02482545

COMPLETED

Assessing the Engagement of Transgender and Other Gender Minority Youth Across the HIV Continuum of Care

NCT02449629

COMPLETED NA

Epic Allies HIV ART Adherence Intervention

NCT02782130

COMPLETED NA

Seeing the World Through Assorted Glasses

NCT02483559

COMPLETED

Role of IL-37 Genetic Variants in Modulating Innate Immune Response to Periodontal Pathogens

NCT03161301

COMPLETED NA

Transcranial Alternating Current Stimulation for Major Depressive Disorder

NCT02339285

COMPLETED NA

Video Counseling for Effective Postpartum Contraception

NCT02438800

COMPLETED NA

STimulation to Improve Auditory haLLucinations

NCT02360228

COMPLETED NA

Feasibility of an Interval Exercise and Nutrition Intervention to Reduce Cardiovascular Disease Risk Factors

NCT02482922

TERMINATED NA

Improvement in Wound Healing With Negative Pressure Wound Therapy for Postoperative Total Hip Arthroplasty

NCT02355691

COMPLETED Phase 1

Phase I Study of HIV 1 Antigen Expanded Specific T Cell Therapy

NCT02208167

COMPLETED NA

Permanent Versus Absorbable Colpopexy Trial

NCT02277925

COMPLETED Phase 1

Effect of Non-Alcoholic Steatohepatitis (NASH) on the Pharmacokinetics of 99mTechnetium-Mebrofenin

NCT02235233

COMPLETED NA

AFIX to Improve HPV Vaccination

NCT02370459

COMPLETED NA

The STRENGTH Study: Shapely Sisters Targeting Realistic Exercise and Nutrition Goals Through Healthy Habits

NCT02253641

COMPLETED NA

Integrated Coping and Awareness Training

NCT02400502

COMPLETED Phase 1

Dose Proportionality of TFV-DP After a Single Dose of GS-7340 in Women

NCT02357602

COMPLETED NA

Our Year of Healthy Living (Formative Research & Intervention)

NCT02330354

COMPLETED

PHASES: Provision of HIV Treatment at ATN Sites: An Evaluation for Stakeholders

NCT02438592

COMPLETED NA

Making Effective Human Papillomavirus (HPV) Vaccine Recommendations

NCT02377843

COMPLETED

Tracking Outcomes in Pain Patients Using Fitness Devices

NCT02420457

COMPLETED NA

Care2BWell: Worksite Wellness for Child Care

NCT02381938

COMPLETED

Genetics of Primary Ciliary Dyskinesia

NCT02389049

COMPLETED NA

Does Physical Therapy Prevent Total Knee Arthroplasty in Patients With End Stage Osteoarthritis

NCT02377102

TERMINATED Phase 2

Treprostinil Sodium Inhalation for Patients At High Risk for ARDS

NCT02370095

COMPLETED

Detection of Brown Adipose Tissue by Magnetic Resonance Imaging

NCT02237872

COMPLETED Phase 4

Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis

NCT02019758

COMPLETED NA

Social Cognition and Interaction Training for Autism

NCT02382172

COMPLETED NA

Analysis of Procedural Times Using Colpassist for Robotic-Assisted Sacrocolpopexy; a Randomized Controlled Trial

NCT02367235

← Previous Page 13 of 23 Next →

Phase Distribution

PhaseTrial count
Phase 1 111
Phase 2 92
Phase 3 13
Phase 4 56

What is open in the University of North Carolina, Chapel Hill pipeline

108 recruiting of 1,109 indexed (10% open); 881 completed (79%).

Phase mix: 69 late (III/IV) vs 203 early (I/II) (early-phase heavy).

Top condition: Obesity (17 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of North Carolina, Chapel Hill: open-pipeline peers nationwide

Peers matched on 1,109 registered trials and 10% open enrollment, not the therapeutic-area sidebar.

University of North Carolina, Chapel Hill sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 8%10%12%14%16%18%20% Total trials Recruiting share University of North Carolina, Chapel HillUniversity of FloridaWake Forest University Health SciencesUniversity of Alabama at BirminghamNYU Langone HealthChildren's Hospitals and Clinics of MinnesotaCytokineticsSanofiOhio University
University of North Carolina, Chapel Hill sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of North Carolina, Chapel Hill sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,109 trials (± recruiting share)

Sponsors near 10% open enrollment (± trial volume)

What to do with this University of North Carolina, Chapel Hill page

1,109 registered trials is a research-attention snapshot, not an endorsement of University of North Carolina, Chapel Hill or any single study.

  • 108 of University of North Carolina, Chapel Hill's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Obesity is the condition University of North Carolina, Chapel Hill studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of North Carolina, Chapel Hill pipeline card: 1,109 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.